Drug Shortage Report for TEVA-LANSOPRAZOLE

Last updated on 2024-03-18 History
Report ID 195649
Drug Identification Number 02280523
Brand name TEVA-LANSOPRAZOLE
Common or Proper name TEVA-LANSOPRAZOLE
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) LANSOPRAZOLE
Strength(s) 30MG
Dosage form(s) CAPSULE (DELAYED RELEASE)
Route of administration ORAL ORAL
Packaging size 500
ATC code A02BC
ATC description DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2023-06-19
Estimated end date Unknown
Actual end date
Shortage status Actual shortage
Updated date 2024-03-18
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v19 2024-03-18 French Compare
v18 2024-03-18 English Compare
v17 2024-02-01 French Compare
v16 2024-02-01 English Compare
v15 2024-01-18 French Compare
v14 2024-01-18 English Compare
v13 2023-11-03 French Compare
v12 2023-11-03 English Compare
v11 2023-10-12 French Compare
v10 2023-10-12 English Compare
v9 2023-10-03 French Compare
v8 2023-10-03 English Compare
v7 2023-08-04 French Compare
v6 2023-08-04 English Compare
v5 2023-07-20 French Compare
v4 2023-07-20 English Compare
v3 2023-06-20 English Compare
v2 2023-06-19 French Compare
v1 2023-06-19 English Compare

Showing 1 to 19 of 19